Autolus Therapeutics AUTL 深 沪
等待开盘 02-02 09:30:00 美东时间
1.37
-0.060
-4.20%
华盛通- 最 高1.445
- 今 开1.43
- 成交量 207.85万股
- 最 低 1.37
- 昨 收 1.43
- 总市值 3.64亿
- 52周最高 2.70
- 市盈率 静 --
- 换手率 0.78%
- 52周最低 1.105
- 委 比 -51.20%
- 总股本 2.66亿
- 历史最高 53.24
- 量 比 1.38
- 振 幅 5.24%
- 历史最低 1.105
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Autolus Therapeutics' Subsidiary Signs Agreement With AGC Biologics To Manufacture, Supply Lentiviral Vector
https://www.sec.gov/ix?doc=/Archives/edgar/data/1730463/000173046326000019/autl-20260121.htm
01-27 05:14
Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket
Shares of Gelteq Ltd (NASDAQ:GELS) rose sharply in pre-market trading after the...
01-14 18:26
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
Autolus Therapeutics Announces Preliminary Q4 2025 AUCATZYL Revenue Of $24M And $75M For Full Year, Issues 2026 Revenue Outlook Of $120M–$135M
Company expects preliminary unaudited AUCATZYL net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025Autolus anticipates full year 2026
01-12 20:08
Autolus To Assess Feasibility Of Cellares' Cell Shuttle Platform To Complement Its Commercial Manufacturing Operations At Nucleus Facility In Stevenage, UK
Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated
01-06 22:04
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform
Autolus is evaluating Cellares' Cell Shuttle platform for enhancing its manufacturing capabilities to support expansion of its CAR T therapy, obe-cel, into new indications, including pediatric and autoimmune diseases. Cell Shuttle enables high-throughput, automated production with consistent quality and lower costs. Autolus aims to assess if this platform can efficiently scale production beyond its current Nucleus facility.
01-06 14:00
美股大行评级 | 潜在涨幅908.06%！Piper Sandler首予Palisade Bio(PALI)"超配"评级，目标价25美元
今日重点评级关注：Needham：维持Autolus Therapeutics"买入"评级，目标价从10美元升至11美元；BTIG：维持Praxis Precision Medicine"买入"评级，目标价从507美元升至843美元
2025-12-30 10:04
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points ...
2025-12-29 23:30
Needham Maintains Buy on Autolus Therapeutics, Raises Price Target to $11
Needham analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $10 to $11.
2025-12-29 20:26
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
